BBP vs VTI
Virtus LifeSci Biotech Products ETF vs Vanguard Morningstar Total Stock Market ETF
Which is better, BBP or VTI?
Mid Cap Growth against Large Cap Blend.
VTI has a lower expense ratio. BBP led over 1Y, 3Y, 5Y and the full window. BBP is less concentrated, with 22.7% of the fund in its ten largest positions against 33.3%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | BBP | VTI |
|---|---|---|
| Expense Ratio | 0.34% | 0.03%Best |
| AUM | $118M | $666.9B |
| Dividend Yield | 0.00% | 1.03% |
| Holdings | 70 | 3,543 |
| YTD Return | +31.35%Best | +13.60% |
| 1Y Return | +53.63%Best | +18.17% |
| 3Y Return (annualized) | +27.59%Best | +23.04% |
| 5Y Return (annualized) | +14.86%Best | +12.14% |
| Volatility (annualized) | 24.0% | 15.4%Best |
| Max Drawdown | -44.3% | -35.0%Best |
| $10,000 over 5 years | $19,991Best | $17,734 |
| Top 10 Weight | 22.7%Best | 33.3% |
| Fund Family | Virtus Investment Partners | Vanguard (US) |
| Category | Equity | Equity |
| Style | Mid Cap Growth | Large Cap Blend |
| Inception | Dec 16, 2014 | May 24, 2001 |
Volatility and max drawdown are measured over the window both funds cover: Dec 17, 2014 to Sep 25, 2026 (11.8 years).
BBP vs VTI growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 11.8 years both funds cover.
BBP vs VTI Performance
Virtus LifeSci Biotech Products ETF (BBP) is an ETF from Virtus Investment Partners and Vanguard Morningstar Total Stock Market ETF (VTI) is an ETF from Vanguard (US). Over the past year BBP returned +53.63% while VTI returned +18.17%. Year to date, BBP is up 31.35% versus a gain of 13.60% for VTI.
Over three years, BBP compounded at +27.59% per year against +23.04% for VTI; over five years the annualized figures are +14.86% and +12.14% respectively. Across the full 12-year window we track, BBP has the edge at +12.70% annualized vs +12.36%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
BBP has been the more volatile fund, with annualized monthly volatility of 24.0% compared with 15.4% for VTI. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -44.3% for BBP and -35.0% for VTI. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.56. They move together some of the time, and apart the rest.
Fees and Cost Over Time
BBP charges 0.34% per year while VTI charges 0.03%. On a $10,000 position that is $34 vs $3 annually, a gap of $31 per year that compounds over a long holding period. On income, BBP currently yields 0.00% against 1.03% for VTI.
Holdings Overlap
86.4% of BBP's money is in holdings VTI also owns. 1.3% of VTI's money is in holdings BBP also owns.
Most of BBP is already inside VTI. Owning both mostly buys the same companies twice.
58 positions in common, counted across the 67 positions we hold weights for in BBP and 3,463 in VTI, against full books of 70 and 3,543.
What only one of them owns
Our book lists 1,121 positions for VTI that do not appear in our book for BBP (96.2% of the fund), and 4 for BBP that do not appear in VTI (6.3%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in BBP | Weight in VTI | Difference |
|---|---|---|---|
| MRNAModerna therapeutics | 3.65% | 0.03% | 3.62% |
| OMEROmeros Corp Com | 2.68% | 0.00% | 2.68% |
| IOVAIovance Biotherapeutics Inc | 2.61% | 0.00% | 2.61% |
| VSTMVerastem Inc | 2.38% | 0.00% | 2.38% |
| PGENPrecigen Corp | 1.97% | 0.00% | 1.97% |
| HALOHalozyme Therapeutics Inc | 1.95% | 0.01% | 1.94% |
| SRPTSarepta Therapeutics Inc | 1.84% | 0.00% | 1.84% |
| AMGNAmgen Inc. | 1.53% | 0.29% | 1.24% |
| RIGLRigel Pharmaceuticals Inc | 1.81% | 0.00% | 1.81% |
| REGNRegeneron Pharmaceuticals, Inc. | 1.69% | 0.11% | 1.58% |
86.4% of BBP is already inside VTI.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, BBP or VTI?
BBP has an expense ratio of 0.34% while VTI charges 0.03%. VTI is the cheaper option, by $31 a year on a $10,000 investment.
Which performed better, BBP or VTI?
Over the past year BBP returned +53.63% vs +18.17% for VTI, so BBP leads on 1-year performance. Over the longest common window we track (12 years), BBP annualized +12.70% vs +12.36% for VTI. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, BBP or VTI?
BBP has been the more volatile fund at 24.0% annualized versus 15.4% for VTI. Worst drawdown: BBP -44.3% vs VTI -35.0%.
Should I hold both BBP and VTI?
BBP and VTI have a monthly-return correlation of 0.56, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between BBP and VTI?
86.4% of BBP's money is in holdings VTI also owns. 1.3% of VTI's is in holdings BBP also owns. They hold 58 positions in common, counted across the 67 positions we hold weights for in BBP and 3,463 in VTI.
Which pays a higher dividend, BBP or VTI?
BBP yields 0.00% while VTI yields 1.03%, so VTI currently pays the higher dividend yield.
Is VTI better than BBP?
VTI has a lower expense ratio. BBP led over 1Y, 3Y, 5Y and the full window. BBP is less concentrated, with 22.7% of the fund in its ten largest positions against 33.3%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.